Dr William Hiatt joins ARCA Biopharma
This article was originally published in Scrip
Executive Summary
Dr William Hiatt has joined ARCA Biopharma (US) as director of clinical and regulatory strategy. He is professor of medicine, professor of cardiovascular research and chief of the section of vascular medicine at the University of Colorado Denver's Anschutz Medical Campus. ARCA is a private company developing genetically targeted therapies for heart failure and other cardiovascular diseases. The company's lead product, Gencaro (bucindolol hydrochloride), is a beta-blocker and mild vasodilator being developed for heart failure and other indications.